Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Eriksson

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Plos One|March 1, 2022
Relationships between Dota 2 expertise and decision-making abilityDaniel Eriksson Sörman, Karl Eriksson Dahl, Daniel Lindmark, et al.
Therapeutic Advances in Hematology|August 2, 2024
Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: <i>post hoc</i> analysis of phase III trials using patient-reported outcomesPriyanka Raheja, Nana Kragh, Linda Bystrická, et al.
Therapeutic Advances in Hematology|June 7, 2023
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: Jan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
ESC Heart Failure|October 10, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failureBrandon K Martinez, Thomas J Bunz, Daniel Eriksson, et al.
Advances in Therapy|June 23, 2023
Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European CountriesEva Funding, Gillian Lowe, Lone H Poulsen, et al.
Bioresource Technology|December 2, 2011
Characterization of Scots pine stump-root biomass as feed-stock for gasificationDaniel Eriksson, Fredrik Weiland, Henry Hedman, et al.
Journal of Market Access & Health Policy|April 25, 2025
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UKNichola Cooper, Sebastian Guterres, Michał Pochopień, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 19, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Obesity Surgery|February 4, 2017
Omentectomy in Addition to Bariatric Surgery-a 5-Year Follow-upDaniel P Andersson, Daniel Eriksson-Hogling, Jesper Bäckdahl, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 9, 2019
Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database AnalysisCraig I Coleman, Reinhold Kreutz, Nitesh Sood, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Plos One|March 1, 2022
Relationships between Dota 2 expertise and decision-making abilityDaniel Eriksson Sörman, Karl Eriksson Dahl, Daniel Lindmark, et al.
Therapeutic Advances in Hematology|August 2, 2024
Long-term efmoroctocog alfa prophylaxis improves perceived pain, mental, and physical health in patients with hemophilia A: <i>post hoc</i> analysis of phase III trials using patient-reported outcomesPriyanka Raheja, Nana Kragh, Linda Bystrická, et al.
Therapeutic Advances in Hematology|June 7, 2023
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: Jan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
ESC Heart Failure|October 10, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failureBrandon K Martinez, Thomas J Bunz, Daniel Eriksson, et al.
Advances in Therapy|June 23, 2023
Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European CountriesEva Funding, Gillian Lowe, Lone H Poulsen, et al.
Bioresource Technology|December 2, 2011
Characterization of Scots pine stump-root biomass as feed-stock for gasificationDaniel Eriksson, Fredrik Weiland, Henry Hedman, et al.
Journal of Market Access & Health Policy|April 25, 2025
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UKNichola Cooper, Sebastian Guterres, Michał Pochopień, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 19, 2018
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, et al.
Obesity Surgery|February 4, 2017
Omentectomy in Addition to Bariatric Surgery-a 5-Year Follow-upDaniel P Andersson, Daniel Eriksson-Hogling, Jesper Bäckdahl, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 9, 2019
Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database AnalysisCraig I Coleman, Reinhold Kreutz, Nitesh Sood, et al.
Pageof 12